Considering the results of this and previous studies, we confirmed that CXCR6 can mediate the cytotoxicity of CD8+MAIT cells to malignant cells in NSCLC immunotherapy, thereby increasing sensitivity to immunotherapy. This evidence concerns the gene CXCR6 and non-small cell lung carcinoma.